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Thalidomide is an anti-inﬂammatory, immunomodulatory, and
antiangiogenic agent used since the 1950s. It is used in the treat-
ment of multiple myeloma, myelodysplastic syndrome (MDS), Beh-
cet's disease, systemic lupus erythematosus, rheumatoid arthritis,
and graft-versus-host disease. The most common adverse effects
of thalidomide are sedation, constipation, nausea, pruritus, neurop-
athy, tremor, rash, and edema.1e3 Among the cutaneous adverse ef-
fects, maculopapular rash has been reported as being commonwith
a frequency of 14% to 16% in the diverse studies.3e5 To our knowl-
edge, leukocytoclastic vasculitis due to thalidomide therapy has
been reported twice previously.2,4 Herein, we report a case of leu-
kocytoclastic vasculitis due to thalidomide therapy used for MDS.
A 49-year-old female was referred from the hematology
department of Mugla Sitki Kocman University Training and
Research Hospital, Turkey with an erythematous rash on the legs
that had been present for 3 days. On physical examination,Figure 1 (A) Purpuric macules and papules on the legs, diameters
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when pressed, with diameters ranging from 5 mm to 10 mm,
were observed on the legs (Figure 1A and 1B). The patient had
been diagnosed with MDS 4 months previously and thus, was tak-
ing 100 mg/d thalidomide for approximately 3 months. The med-
ical history showed no other drug use. Laboratory tests were as
follows: hemoglobin, 9.75 g/dL; hematocrit, 29.2%; white blood
cells, 53,000/mm3; platelets, 286,000/mm3; blood urea, 26 mg/
dL; creatinine, 0.62 mg/dL; and C-reactive protein, 7.28 mg/dL.
Urine analysis was normal. A punch biopsy was taken from the
skin lesions. The histopathological examination showed intrader-
mal vasculitic reaction with neutrophils, scattered eosinophils,
and ﬁbrinoid necrosis compatible with vasculitic drug eruption
(Figure 2A and 2B). Thalidomide therapy was stopped and oral
antihistamine was started. The eruption cleared within 10 days.
When we reintroduced thalidomide therapy 2 weeks later, the
eruption recurred within 3 days. Consequently, thalidomide ther-
apy was withdrawn permanently.ranging from 5-mm to 10-mm; (B) closer image of the lesions.
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Figure 2 (A, B) Intradermal vasculopathic reaction with neutrophils and scattered eosinophils (H&E, original magniﬁcation 200).
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fects involving down-regulation of tumor necrosis factor-a, up-
regulation of adhesion molecules, and inhibition of angiogenesis.1
It is used in the treatment of various autoimmune diseases and he-
matological diseases. The most common cutaneous side effect is
maculopapular rash; vasculitic eruption in response to thalidomide
has previously been reported only twice.2e5
Drug-induced vasculitis is characterized by inﬂammation of
blood vessels due to the use of various pharmacological agents.6
The most common drugs responsible are penicillin, nonsteroidal
anti-inﬂammatory drugs, sulfonamides, and cephalosporins.
Drug-induced vasculitis is considered to be triggered by the depo-
sition of immune complexes in postcapillary venules. Drug-induced
vasculitis generally occurs within 7e21 days of the ﬁrst use of the
drug, however, it can occur within 3 days of the second use of the
responsible drug.7 Histopathological examination demonstrating
inﬂammatory inﬁltration involving eosinophils and challenge tests
may be useful in distinguishing drug-induced vasculitis from idio-
pathic vasculitis.6 In our patient, the repeated use of thalidomide
resulted in the vasculitic rash on the legs. The histopathological
analysis with eosinophilic inﬁltration conﬁrmed our diagnosis as
drug-induced leukocytoclastic vasculitis.
In the differential diagnosis, insect bites, erythema multiforme,
pityriasis lichenoides andvarioliformis acute, acutemeningococcemia,
rickettsial infections, and viral exanthemas should be considered.8
Although systemic steroid treatment may be required in the
case of vasculitis with systemic involvement, drug-induced
vasculitis generally improves with the withdrawal of the respon-
sible drug.7 In our patient, the eruption cleared in a short time
with the discontinuation of thalidomide and initiation of antihis-
tamine therapy. To the best of our knowledge, our patient is the
third case of vasculitic drug eruption due to thalidomide. The
outcome of the disease and the therapeutic approach are altered
in drug-induced vasculitis, therefore a detailed investigation
should be carried out on the medical history and drug use. Phy-
sicians should be aware of the possibility of leukocytoclastic
vasculitis due to thalidomide.Asude Kara*, Asli Akin Belli
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